Browsing by Subject "Cutaneous adverse events, Metastatic melanoma, B-RAF inhibitors, Immune checkpoint blockade, Vemurafenib/cobimetinib, DRESS syndrome"
Now showing items 1-1 of 1
-
Cutaneous adverse reactions in B-RAF positive metastatic melanoma following sequential treatment with B-RAF/MEK inhibitors and immune checkpoint blockade or vice versa. A single-institutional case-series
(2018-12-16)Background With the advent of immune-checkpoint inhibitors and targeted treatments (TT), there have been unprecedented response rates and survival in advanced melanoma, but the optimal sequencing of these two treatments ...